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Objective and design: A prospective, randomised, double-blinded, clinical trial was performed at a level 1 trauma
centre to determine if a prostacyclin analogue, epoprostenol (Flolan®), could attenuate systemic inflammatory
response in patients with severe traumatic brain injury (TBI).
Subjects: 46 patients with severe TBI, randomised to epoprostenol (n = 23) or placebo (n = 23).
Treatment: Epoprostenol, 0.5 ng · kg-1 · min-1, or placebo (saline) was given intravenously for 72 hours and then
tapered off over the next 24 hours.
Methods: Interleukin-6 (IL-6), interleukin-8 (IL-8), soluble intracellular adhesion molecule-1 (sICAM-1), C-reactive
protein (CRP), and asymmetric dimethylarginine (ADMA) levels were measured over five days. Measurements were
made at 24 h intervals ≤24 h after TBI to 97–120 h after TBI.
Results: A significantly lower CRP level was detected in the epoprostenol group compared to the placebo group
within 73–96 h (p = 0.04) and within 97–120 h (p = 0.008) after trauma. IL-6 within 73–96 h after TBI was significantly
lower in the epoprostenol group compared to the placebo group (p = 0.04). ADMA was significantly increased
within 49–72 h and remained elevated, but there was no effect of epoprostenol on ADMA levels. No significant
differences between the epoprostenol and placebo groups were detected for IL-8 or sICAM-1.
Conclusions: Administration of the prostacyclin analogue epoprostenol significantly decreased CRP and, to some
extent, IL-6 levels in patients with severe TBI compared to placebo. These findings indicate an interesting option for
treatment of TBI and warrants future larger studies.
Trial registration: ClinicalTrials.gov Identifier, NCT01363583
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Following traumatic injuries with or without severe trau-
matic brain injury (TBI), an inflammatory response is
induced both in the brain and in the systemic circulation
(Holmin et al. 1998; Lu et al. 2009). Severe injury is associ-
ated with a systemic host-defence reaction – known as
systemic inflammatory response syndrome (SIRS) – that
can progress into multiple organ failure (Lenz et al. 2007).* Correspondence: magnus.hultin@umu.se
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in any medium, provided the original work is pExperimental studies and clinical studies in trauma
patients have shown that increased production of in-
flammatory mediators is associated with SIRS and
subsequent organ failure (Lenz et al. 2007; Stahel et al.
2007), and several different inflammatory mediators
have been used to measure the inflammatory response
(Lu et al. 2009; Lenz et al. 2007).
Modulating the systemic pro-inflammatory response and
reducing cytokine overproduction might be an effective
therapeutic strategy for preventing organ failure due to
SIRS after traumatic injuries, including severe TBI
(Neunaber et al. 2011). Whether reducing the inflammatorys is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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however, is an unanswered question (Lenz et al. 2007). The
endogenous substance prostacyclin, which is released from
vascular endothelial cells, has the potential to alter the
systemic inflammatory response. In experimental studies,
prostacyclin has been shown to inhibit leucocyte acti-
vation and adhesion to the endothelium as well as to
reduce already established leucocyte adhesion. Prosta-
cyclin has also been suggested to scavenge oxygen free
radicals and to reduce the synthesis of mediators of the
SIRS cascade (Moncada et al. 1976; Jones and Hurley
1984; Scheeren and Radermacher 1997). Reduced pro-
duction and/or effects of endogenous prostacyclin due
to an imbalance in the prostaglandin-thromboxane
pathways have been found experimentally to be associ-
ated with TBI (Orfeo et al. 1994).
In this study, interleukin-6 (IL-6), interleukin-8 (IL-8),
soluble intracellular adhesion molecule-1 (sICAM-1), and
C-reactive protein (CRP) were used as markers for the
systemic inflammatory response. IL-6 is one of the most
studied pro-inflammatory cytokines after trauma (Jawa
et al. 2011). IL-8 is produced by a large variety of cells,
including macrophages and monocytes, and functions
as a chemotactic cytokine by drawing neutrophils to
the site of tissue injury or inflammation (Charo and
Ransohoff 2006). The adhesion molecule sICAM-1 forms
a connection between leucocytes and the endothelium
and is necessary for adequate transmigration of leucocytes
through the endothelium. This molecule, therefore, re-
flects the degree of endothelial cell activation (Lawson
and Wolf 2009). CRP is a well known and widely used
non-specific marker for inflammation (Du Clos 2000).
In addition, asymmetric dimethylarginine (ADMA), an
endogenous inhibitor of nitric oxide, was used as a marker
for endothelial dysfunction (Böger 2003).
The aim of this study was to evaluate the effect of epo-
prostenol versus placebo on systemic inflammatory re-
sponse and endothelial dysfunction during the initial five
days after severe TBI. The hypothesis was that epoproste-




This prospective, double-blinded, randomised, clinical
study was conducted with a primary aim of evaluating
the cerebral microcirculatory effect of a prostacyclin
analogue (epoprostenol, Flolan®, Glaxo SmithKline) com-
pared to placebo (saline) in the injured brain. Results on
cerebral microcirculation and clinical outcome have
been published previously (Olivecrona et al. 2009). The
part of the study reported here evaluates the effects of
epoprostenol on the systemic inflammatory response and
endothelial function by measuring the levels of CRP, IL-6,IL-8, sICAM-1, and ADMA. The study has been registered
as a drug study; ClinicalTrials.gov Identifier: NCT01363583
(http://clinicaltrials.gov/ct2/show/NCT01363583).
Randomization was performed by means of the ran-
dom number method. All staff members and investiga-
tors were blinded as to treatment group throughout the
study period. Patients with severe TBI admitted to the
Intensive Care Unit (ICU) at Umeå University Hospital,
Sweden between January 1, 2002, and December 31, 2005,
were eligible to be recruited into the study if they fulfilled
the inclusion criteria below.
The levels of the inflammatory markers CRP, IL-6, IL-8,
sICAM-1, and ADMA (as a marker for endothelial dys-
function) were measured daily between 9 a.m. and 12 a.m.
Ethics
The Local Research Ethics Committee of Umeå University,
Sweden, approved the study protocol and, because the
study was classified as a drug study, it was also approved
by the Medical Products Agency of Sweden. Written
informed consent was obtained upon arrival from next
of kin. Delayed informed consent from the patient was
obtained at the three-month follow-up if possible.
Inclusion and exclusion criteria
The inclusion criteria were severe TBI defined as Glasgow
Coma Scale (GCS) score ≤8 at the time of sedation and
intubation, age between 15 years and 70 years, arrival
at Umeå University Hospital within 24 hours from the
accident, and cerebral perfusion pressure (CPP) ≥10 mmHg
at first measurement.
Exclusion criteria were pregnant or lactating women,
known bleeding diathesis, known allergy to epoprostenol,
penetrating head trauma, or being discharged alive from
the ICU within 72 hours.
Treatment
An intracranial pressure targeted treatment protocol,
based on the Lund concept, was used. This treatment
approach for severe TBI has been thoroughly described
in previous publications (Grände 2006; Naredi et al. 2001).
Normovolemia and normotension was aggressively main-
tained and no hypotensive events were recorded during
administration of study drugs, neither in the control group
nor in the intervention group.
Scoring
The scoring systems used to describe the severity of injury
included the GCS, the Injury Severity Score (ISS), the Acute
Physiologic and Chronic Health Evaluation II (APACHE II),
and the Sequential Organ Failure Assessment (SOFA)
(Teasdale and Jennett 1974; Baker et al. 1974; Knaus et al.
1985; Vincent et al. 1996). GCS was collected before
sedation and intubation. The SOFA score evaluates the
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tory, haematological, hepatic, cardiovascular, renal, and
central nervous system) from zero (no organ failure) to
four (severe organ failure). The worst parameter per day
was registered without consideration to duration. Severe
organ failure was defined as SOFA ≥3 (Knaus et al. 1985).
Drug
Prostacyclin (epoprostenol, Flolan®, Glaxo SmithKline)
or placebo (saline) was administered intravenously at
rate of 0.5 ng · kg-1 · min-1. The hospital pharmacy pre-
pared the drugs according to the randomization number
and delivered them in identical boxes labelled with test
drug and randomization number. The epoprostenol or pla-
cebo infusion was started as soon as possible after arrival at
the ICU and was continued for 72 hours and then tapered
off during the next 24 hours. The endogenous production
of prostacyclin has been estimated to be in the range of
60 pg · kg-1 · min-1 to 0.1 ng · kg-1 · min-1 (Jones and Hurley
1984; Scheeren and Radermacher 1997). The epoprostenol
dose used in this study, 0.5 ng · kg-1 · min-1, was based on
two previous clinical studies, and this dose was not as-
sociated with any adverse events as thrombocytopenia,
hypotension or increased pulmonary shunt (Naredi et al.
2001; Grände et al. 2000; Chin et al. 2009).
Data
An ICU monitoring system (Marquette Solar, General
Electric Medical Systems) and an ICU medical records
computerised system (PICIS Inc., Wakefield, MA, USA)
collected all physiological data continuously.
The exact time of the accident was recorded and both
the inflammatory markers (CRP, IL-6, IL-8, and sICAM-1)
and the marker for endothelial dysfunction (ADMA) were
linked to the time of the TBI and the results are presented
in 24 h intervals after TBI (≤24 h, 25–48 h, 49–72 h,
73–96 h, and 97–120 h).
Hospital days (0–5) were used for SOFA scoring. The
definition of hospital days is based on the fact that all
sampling and summation of data at our ICU, including
SOFA score, is made in 24 hours intervals starting at
7 a.m. every day. Day zero starts from the hour the patient
arrives at the ICU and lasts until 7 a.m. the following
morning. Days 1–5 start at 7 a.m. and last for 24 hours.
SOFA was scored daily for respiration, circulation,
coagulation, liver, and kidney failure. The central ner-
vous system was not scored because the patients were
continuously sedated.
Cytokines, ADMA, and laboratory parameters
Blood samples for cytokines were worked up immediately
after being drawn from the patients. Serum was separated
by centrifugation at 3000 rpm at room temperature andsamples were frozen within 30 minutes in separate test
tubes and stored at −80°C until the assays for cytokines
were performed. The levels of serum IL-6, IL-8 (Pierce
Biotechnology Inc., Rockford, IL, USA), and sICAM-1
(Biosource International Inc., Camarillo, CA, USA) were
determined by double anti-body enzyme linked immuno-
sorbent assays (ELISA) according to the manufacturer’s
procedure. All measurements were performed in dupli-
cate. Reference levels, according to the manufacturer, were
43 pg/mL for IL-6, 8.6 pg/mL for IL-8, and 230 ng/mL
for sICAM-1.
To analyse ADMA, a previously published method
based on HPLC separation of OPA-derivatized basic
amino acids was used with minor modifications (Teerlink
et al. 2002; Andersson et al. 2010). All reagents and
chemicals for the analysis of ADMA were from Sigma-
Aldrich (Stockholm, Sweden). CRP and the daily blood
sampling necessary for SOFA scoring (platelets, biliru-
bin, creatinine, and arterial blood gases) were analysed
by standard procedures at the accredited University
Hospital laboratory.
Clinical outcome
Patient outcome three months after TBI was evaluated
with the Glasgow Outcome Scale (GOS) (Teasdale and
Jennett 1976). The GOS is a five-point scale where a
score of 5 or 4 is defined as a favourable outcome and a
score of 3, 2, or 1 as an unfavourable outcome.
Statistics
The statistical software package Prism (version 5.0,
GraphPad Software Inc., CA, USA) was used for statis-
tical analyses. Mann-Whitney’s test was used for com-
parison of parameters between the groups (epoprostenol
vs. placebo). The Kruskal-Wallis test, using Dunn’s mul-
tiple comparison test for post-hoc analysis, was used for
comparison of parameters at different time points within
each group. Fischer’s exact test was used for comparison
of severe organ failure, antibiotic treatment, multi-trauma,
and surgery between the groups (epoprostenol vs. placebo).
Statistical significance was defined as p <0.05. Data are pre-
sented as mean ± SD, median (range), or per cent (%).
Results
Patient characteristics
In total, 89 patients with severe TBI with or without re-
lated traumatic injuries were admitted to Umeå University
Hospital from 2002 to 2005. However, only 48 individ-
uals fulfilled the inclusion criteria for the study. Exclu-
sion was due to a GCS score >8 at the time of sedation
and intubation (n = 18), too young or too old (n = 6),
CPP <10 mmHg at insertion of the intracranial pressure
monitoring device (n = 6), arrival >24 hours after TBI
(n = 3), denial of inclusion (n = 2), or for other reasons,
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inclusion (n = 6). None of the patients were excluded
due to discharge from ICU within 72 h. The study
flow-chart is described in detail in the primary end-
point study (Olivecrona et al. 2009). In two patients, no
samples for cytokines were obtained so the results in
this study are based on 46 patients randomized to 23 in
the epoprostenol group and 23 in the placebo group.
No significant differences in baseline values were seen
between the two groups regarding age, sex, GCS, ISS,
AIS head, APACHE II, number of multiple injuries,
number of patients receiving antibiotics, number of
patients in need of surgery, or time to start of the study
infusion (Table 1). In the placebo group, only neurosur-
gery (craniotomy) was performed. In the epoprostenol
group, facial fracture reconstruction (three patients), and
major orthopaedic surgery (two patients) were also per-
formed in addition to neurosurgery (Table 1). In the
epoprostenol group, 6 patients had one or two dilated
pupils at the time of endotracheal intubation, i.e. at the
time of first GCS score, compared to 5 patients in the
placebo group. The prophylactic use of antibiotics was
common in both groups due to fractures of the skull or
face and suspected or verified cerebral spinal fluid leaks.
No verified infections were noted during the 5-day study
period. There were no adverse effects as hypotension or
thrombocytopenia in this study associated with the
intravenous infusion of epoprostenol during or after the
time of administration.
Markers for systemic inflammation and endothelial
dysfunction
Before start of the epoprostenol/placebo infusion (first
sample, ≤24 h after trauma), the levels of IL-6, IL-8,




APACHE II, median (range)
GCS, median (range)
ISS, median (range)
AIS Head, median (range)
Multi-trauma, n (%)
Antibiotic treatment, n (%)
Surgery, n (%)
Time from accident to start of study infusion in minutes (mean ± SD)
Gender F = Female, M =Male.
APACHE II = Acute Physiologic and Chronic Health Evaluation II.
GCS = Glasgow Coma Scale at the time of sedation and intubation.
ISS = Injury Severity Score.
AIS = Abbreviated Injury Scale.
ns = non-significant.different between the epoprostenol and the placebo
group (Figures 1, 2, 3, 4 and 5).
In the epoprostenol group, IL-6 increased non-
significantly from ≤24 h to 25–48 h after trauma. IL-6
was significantly lower 73–96 h after trauma in the epo-
prostenol group compared to the placebo group (Figure 1).
There were no statistically significant differences in IL-8
or sICAM-1 concentrations within or between groups
0–120 h after TBI (Figures 2 and 3). CRP increased sig-
nificantly from ≤24 h to 25–48 h after TBI in both
groups (p <0.05, Figure 4). The epoprostenol group had
significantly lower CRP levels at 73–96 h (p < 0.05) and
97–120 h (p < 0.01) after TBI compared to the placebo
group. There was a significant increase in ADMA levels
over time in both groups, but there was no significant
difference between the epoprostenol and the placebo
groups (Figure 5).
Organ failure
There were no statistically significant differences in the
frequency of organ failure between the groups according
to SOFA score on days 1–5 (Table 2).
Outcome
There was no significant statistical difference in outcome
between the groups three months after TBI, and 13/23
(57%) of the patients in the epoprostenol group had a
favourable outcome (GOS 4 or 5) compared to 11/23
(48%) in the placebo group. Mortality three months after
TBI was 9% (2/23) in the epoprostenol group compared
to 17% (4/23) in the placebo group.
Discussion
This is the first clinical trial to investigate the systemic
inflammatory modulating effect of the endogenousEpoprostenol Placebo
29 (15–63) 34 (16–63) ns
10/13 7/16 ns
20 (12–29) 21 (14–32) ns
5 (3–8) 6 (3–8) ns
29 (9–50) 29 (9–43) ns
5 (3–5) 4 (3–5) ns
17/23 (74) 14/23 (61) ns
22/23 (96) 21/23 (91) ns
17/23 (74) 19/23 (79) ns
1131 ± 345 987 ± 310 ns
Figure 1 IL-6 in pg/mL in patients treated with epoprostenol or placebo. IL-6, IL-8, sICAM-1, CRP, and ADMA were measured ≤24 h, 25–48
h, 49–72 h, 73–96 h, and 97–120 h after trauma. These time ranges are denoted as 24, 48, 72, 96, and 120, respectively, in the figures. Values ≤24
hours were all sampled before the start of epoprostenol (E) or placebo (P) infusion. The numbers of patients at each time point are indicated in
parentheses. Data are presented as Box plots. The horizontal line within the box indicates the median, the 25th to 75th percentiles are within the
box, and the minimum and maximum values are shown with error bars. Dotted line = 43 pg/mL (reference value for IL-6 according to the
manufacturer). *Statistically significant difference between the epoprostenol and the placebo group within 73–96 hours after trauma (p = 0.04,
Mann-Whitney’s test).
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study in patients with trauma and severe TBI. The main
endogenous role of prostacyclin is thought to be regula-
tion of the interactions between the vascular endothe-
lium and the blood to prevent aggregation and adhesion
of platelets and leucocytes. Treatment with prostacyclinFigure 2 IL-8 in pg/mL in patients treated with epoprostenol or place
manufacturer). For details see legend to Figure 1.theoretically possesses the potential to influence the in-
flammatory response (Moncada et al. 1976; Jones and
Hurley 1984; Scheeren and Radermacher 1997).
All patients in this study had a considerable inflam-
matory response, as has been previously described in
patients with TBI (Stanisic et al. 2012). CRP levelsbo. Dotted line = 8.6 pg/mL (reference value according to the
Figure 3 sICAM-1 in ng/mL in patients treated with epoprostenol or placebo. Dotted line = 230 ng/mL (reference value according to the
manufacturer). For details see legend to Figure 1.
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Thereafter, CRP decreased more rapidly in the epopros-
tenol group resulting in a significantly lower CRP level
at 73–120 hours after TBI in the epoprostenol group
compared to the placebo group.
The level of IL-6 correlates with the degree of inflam-
mation, and serum levels of IL-6 have been shown to
correlate with severity of injury, the occurrence of





























Figure 4 CRP in mg/L in patients treated with epoprostenol or placeb
laboratory at Umeå University Hospital is <10 mg/L). *Statistically significan
73–96 h (p = 0.04, Mann-Whitney’s test) and 97–120 h after trauma (p = 0.0Prostacyclin had a limited modulating effect on IL-6 in
this study. IL-6 concentrations initially increased non-
significantly in the epoprostenol group, but thereafter
decreased rapidly. An early increase, followed by rapid
decrease, in IL-6 levels after prostacyclin administration
has been observed previously in an experimental study
(Ohta et al. 2005).
In this study, IL-8 levels were not significantly different
























o. Dotted line = 10 mg/L (the reference value at the accredited
t difference between the epoprostenol and the placebo group within
08, Mann-Whitney’s test). For details see legend to Figure 1.
Figure 5 ADMA in μmol/L in patients treated with epoprostenol or placebo. No statistically significant differences were seen between
the groups. ADMA levels in both groups were significantly higher 72 h, 96 h, and 120 h after trauma compared to the 24 h sample (p < 0.001,
Kruskal-Wallis test). Dotted line = 0.25 ± 0.12 μmol/L (the mean ADMA level in a reference material of healthy subjects). For details see legend
to Figure 1.
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influence on the chemotactic IL-8 cytokine might be small
or non-existent (Charo and Ransohoff 2006).
The inflammatory marker sICAM-1, which mediates
the translocation of leucocytes through the endothelium,
did not increase after TBI nor was it affected by prosta-
cyclin in this study. This could be due to the fact that
sICAM-1, as a marker for endothelial dysfunction, is
not substantially expressed after traumatic injuries (Du
Clos 2000).
Elevated levels of ADMA, which inhibit the produc-
tion of nitric oxide, lead to impaired endothelium-
dependent vasodilation and increased leucocyte/platelet
adhesion (Böger 2003; Siekmeier et al. 2008). No reports
exist concerning the occurrence of endothelial dysfunc-
tion, as measured with ADMA, after TBI. In this study,
ADMA increased significantly in both groups, and thisTable 2 Severe organ failure, measured with the
Sequential Organ Failure Assessment (SOFA) Day 1–5
Organ system Epoprostenol Placebo
Respiration 30/111 (27%) 32/113 (28%) ns
Circulation 8/112 (7%) 10/114 (9%) ns
Coagulation 6/114 (5%) 1/112 (1%) ns
Liver function 0 (0%) 0 (0%) ns
Renal function 0 (0%) 0 (0%) ns
Number of days with SOFA ≥3 of all registered SOFA scores on days 1–5 in
different organ systems are given in numbers and percentage.
The SOFA scores the degree of organ failure in six different systems
(respiratory, haematological, hepatic, cardiovascular, renal, and central nervous
system) from zero (no organ failure) to four (severe organ failure). The worst
parameter per day in each system was registered without consideration for
duration. Severe organ failure is defined here as SOFA ≥3. Central nervous
system SOFA was not scored due to the fact that the patients were treated
with continuous intravenous sedation.
ns = non-significant.indicates that a systemic pro-inflammatory response
might induce endothelial dysfunction.
Severe trauma induces a systemic inflammatory response
that can lead to capillary leakage and circulatory instability
(Lenz et al. 2007; Stahel et al. 2007). Prostacyclin would
theoretically be able to decrease capillary leakage, intersti-
tial oedema, and the development of organ failure. In a
previous experimental study, prostacyclin reduced volume
loss after lipopolysaccharide-induced meningitis (Jungner
et al. 2009). However, in the present study, even though
prostacyclin had a modulating effect on CRP and IL-6 no
difference was found in the incidence of organ failure.
Reduction of the inflammatory response after TBI
has been tested using glucocorticoids as a pharmaco-
logical agent. Even though factors other than the
anti-inflammatory effect of glucocorticoids could be
responsible for the reduced inflammatory response, the
CRASH study showed that corticosteroids were actually
associated with a higher risk of death than placebo in TBI
patients (Roberts et al. 2004). This implies that excessively
inhibiting the systemic inflammatory response is not
associated with a favourable outcome in TBI patients.
Prostacyclin, with a half-life of a few minutes and with
a distinct endothelial point of action, could be an alter-
native as modulator of the systemic inflammatory re-
sponse, but further studies are needed.
This is a study with a limited number of patients. The
dose of epoprostenol in this study could have been too
low and/or the treatment time too short to have had a
more prominent effect on the systemic inflammatory
response. To what extent a decrease in the systemic
pro-inflammatory response might be beneficial for patients
with traumatic injuries, including severe TBI, remains to
be investigated.
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In this randomised placebo-controlled clinical study, the
prostacyclin analogue epoprostenol significantly modulated
and reduced the systemic pro-inflammatory response as
measured by CRP and, to a lesser extent, IL-6 levels in
patients with severe TBI compared to placebo.
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